Admera Health Announces Availability of Psychiatric Specific Report, PGxPsych™, for its PGxOne™ Plus Pharmacogenomics Test

South Plainfield, NJ – June 26, 2018 - Today, Admera Health (, announced the availability of a psychiatric specific report for its PGxOne™ Plus pharmacogenomics test. PGxOne™ Plus is a laboratory developed test that includes over 50 genes, over 200 DNA variants (affecting drug metabolism, transportation, and activation), and provides [...]

Admera Health Launches New Tests for Cancer Supportive Care and Liquid Biopsy, Now Provides a Comprehensive Portfolio of Oncology Products

SOUTH PLAINFIELD, N.J., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Today, Admera Health ( announced the launch of multiple laboratory developed tests: PGxOnco™, for cancer supportive care, and LiquidGx™, a suite of liquid biopsy based tests for tumor profiling and drug resistance monitoring. Admera initially unveiled these tests on October [...]

Admera Health Expands Asian Footprint with Three Strategic Partnerships

South Plainfield, NJ – September 12, 2017 – Today, Admera Health announced agreements expanding Admera’s portfolio of molecular diagnostics to Asia, including but not limited to Singapore, Hong Kong, Korea and Taiwan. Admera Health, a molecular diagnostic company, offers the most comprehensive pharmacogenomics testing services available, its PGxOne™ Plus [...]

Columbia University Medical Center’s Center for Biomedical Informatics Collaborates with Admera Health in a Clinical Study, Evaluating Pharmacogenetics in Psychiatric Medications

SOUTH PLAINFIELD, NJ – July 25, 2017 - Admera Health, an advanced molecular diagnostic laboratory, has been selected by Columbia University Medical Center’s Center for Biomedical Informatics to supply its powerful 50-gene pharmacogenomic testing panel for major study to test comprehensive pharmacogenomic testing on treatment of major depressive disorders. The [...]

Load More Posts

Media Requests

Please contact us with any questions, interview requests, or other related inquiries.